CSL's Paul Perreault Receives Healthcare CEO Enterprise Award from Philadelphia Alliance for Capital and Technologies

The award recognizes Perreault's leadership, vision and his role in strengthening and promoting the life sciences industry in the region.

News provided by

CSL Behring

May 13, 2016, 10:15 ET

KING OF PRUSSIA, Pa., May 13, 2016 /PRNewswire/ -- Philadelphia Alliance for Capital and Technologies (PACT), an affiliate of the Greater Philadelphia Chamber of Commerce, has recognized CSL CEO and Managing Director Paul Perreault with its 2016 Healthcare CEO Award. The award is based on criteria such as management accomplishments and philosophy, leadership and industry and market impact.

CSL CEO and Managing Director Paul Perreault has received the 2016 Healthcare CEO Award from Philadelphia Alliance for Capital and Technologies, an affiliate of the Greater Philadelphia Chamber of Commerce. The award is based on criteria such as management accomplishments and philosophy, leadership and industry and market impact. Award criteria also include an ability to attract and retain talented resources, company milestones including financial accomplishments and a strategy for continued company success, and community/industry involvement.

Award criteria also include an ability to attract and retain talented resources, company milestones including financial accomplishments and a strategy for continued company success, and community/industry involvement. PACT, which was established to drive entrepreneurship and innovation in the Philadelphia area, also takes into consideration contributions to strengthening and promoting the life sciences industry.

Paul Perreault, CSL's CEO and Managing Director, said he is honoured to accept the award on behalf of CSL and its 16,000 employees worldwide. "After 100 years of making lifesaving therapies, we have the shared feeling that we are just getting started," Perreault said. "Our promise has never been stronger, and we will continue to unlock the potential of therapeutic proteins to save lives and protect the health of people living with rare and serious conditions."

About CSL Behring
CSL Behring is a global biotherapeutics leader, which is driven by its promise to save lives. Focused on serving patients' needs by using the latest technologies, we develop and deliver innovative therapies that are used to treat coagulation disorders, primary immune deficiencies, hereditary angioedema, inherited respiratory disease, and neurological disorders. The company's products are also used in cardiac surgery, organ transplantation, burn treatment and to prevent hemolytic disease of the newborn.

CSL Behring operates one of the world's largest plasma collection networks, CSL Plasma. The parent company, CSL Limited (ASX:CSL), headquartered in Melbourne, Australia, employs more than 16,000 people with operations in more than 30 countries. For more information visit www.cslbehring.com and follow us on www.Twitter.com/CSLBehring.

Media Contact
Name: Chris Florentz
Office: 610-878-4316; Mobile: 484-238-8509
Email: [email protected]

Photo - http://photos.prnewswire.com/prnh/20160513/367301
Logo - http://photos.prnewswire.com/prnh/20100914/PH63692LOGO

SOURCE CSL Behring